JP2007508326A5 - - Google Patents

Download PDF

Info

Publication number
JP2007508326A5
JP2007508326A5 JP2006534467A JP2006534467A JP2007508326A5 JP 2007508326 A5 JP2007508326 A5 JP 2007508326A5 JP 2006534467 A JP2006534467 A JP 2006534467A JP 2006534467 A JP2006534467 A JP 2006534467A JP 2007508326 A5 JP2007508326 A5 JP 2007508326A5
Authority
JP
Japan
Prior art keywords
received
group
intron
peg
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006534467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007508326A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/033739 external-priority patent/WO2005037274A1/en
Publication of JP2007508326A publication Critical patent/JP2007508326A/ja
Publication of JP2007508326A5 publication Critical patent/JP2007508326A5/ja
Pending legal-status Critical Current

Links

JP2006534467A 2003-10-11 2004-10-12 Hcv感染のための組み合わせ治療 Pending JP2007508326A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51073303P 2003-10-11 2003-10-11
PCT/US2004/033739 WO2005037274A1 (en) 2003-10-11 2004-10-12 Combination therapy for hcv infection

Publications (2)

Publication Number Publication Date
JP2007508326A JP2007508326A (ja) 2007-04-05
JP2007508326A5 true JP2007508326A5 (https=) 2007-10-11

Family

ID=34465143

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006534467A Pending JP2007508326A (ja) 2003-10-11 2004-10-12 Hcv感染のための組み合わせ治療

Country Status (17)

Country Link
US (1) US20050112093A1 (https=)
EP (1) EP1670462A1 (https=)
JP (1) JP2007508326A (https=)
KR (1) KR20060120037A (https=)
CN (1) CN1882335A (https=)
AR (1) AR045870A1 (https=)
AU (1) AU2004281747A1 (https=)
BR (1) BRPI0415249A (https=)
CA (1) CA2541857A1 (https=)
IL (1) IL174864A0 (https=)
MX (1) MXPA06004077A (https=)
NO (1) NO20062104L (https=)
PE (1) PE20050477A1 (https=)
RU (1) RU2006115916A (https=)
TW (1) TW200528104A (https=)
WO (1) WO2005037274A1 (https=)
ZA (1) ZA200602912B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1019A (en) 1996-10-18 2001-10-16 Vertex Pharma Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
UY28500A1 (es) 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
US20120201883A1 (en) * 2004-05-21 2012-08-09 Accu-Break Technologies, Inc Antiviral compositons
TWI437990B (zh) * 2004-10-29 2014-05-21 Vertex Pharma Vx-950之醫藥用途
AU2006275413B2 (en) * 2005-08-02 2012-07-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
WO2007109080A2 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
WO2008106058A2 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
FR2928146B1 (fr) * 2008-02-28 2010-02-19 Saint Gobain Isover Produit a base de fibres minerales et son procede d'obtention.
PE20110343A1 (es) * 2008-09-17 2011-06-25 Boehringer Ingelheim Int Combinacion de inhibidor de la proteasa ns3 de hcv con interferon y ribavirina
WO2010093843A2 (en) * 2009-02-12 2010-08-19 Vertex Pharmaceuticals Incorporated Hcv combination therapies
EP2450051A4 (en) * 2009-06-30 2012-12-19 Meiji Seika Pharma Co Ltd MEDICAL AGENT AND METHOD FOR THE TREATMENT OF HARD-ANGLE CHRONIC HEPATITIS C
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
DE112012002748T5 (de) 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
WO2017062840A1 (en) * 2015-10-09 2017-04-13 Trek Therapeutics, Pbc Combination therapy for the treatment of hepatitis c virus
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
WO2017223178A1 (en) * 2016-06-21 2017-12-28 Trek Therapeutics, Pbc Treating viral infections with impdh inhibitors
KR101991365B1 (ko) * 2017-03-14 2019-06-21 국립암센터 C형 간염 바이러스 질환 치료를 위한 리고세르팁의 신규 용도
CN109745315B (zh) * 2019-03-08 2021-04-16 中国农业科学院兰州兽医研究所 一种Merimepodib在制备预防口蹄疫病毒感染的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2252465C (en) * 1996-04-23 2007-07-03 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
CA2331823A1 (en) * 1998-05-15 1999-11-25 Schering Corporation Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection
US6824769B2 (en) * 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
AU2003249659A1 (en) * 2002-05-31 2003-12-19 Schering Corporation Combination therapy for rna virus infections involving ribavirin and impdh inhibitors

Similar Documents

Publication Publication Date Title
JP2007508326A5 (https=)
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
JP2005518433A5 (https=)
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
FI3782612T3 (fi) Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
MY148773A (en) Galenic formulations of organic compounds
AU3846901A (en) Oral, nasal and pulmonary dosage formualtions of copolymer 1
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
MY136136A (en) Pharmaceutical compositions containing terbinafin and use thereof
TN2010000135A1 (en) Galenical formulations of organic compounds
WO2009026473A3 (en) Stabilized therapeutic compositions and formulations
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
PT1425005E (pt) Composicao farmaceutica que compreende lumiracoxib
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
WO2007131070A3 (en) Compositions, dosage forms and methods of treating emesis
JP2004525940A5 (https=)
UA102111C2 (uk) Фармацевтична композиція у вигляді разової пероральної дози, що містить леводопу, карбідопу і ентакапон або їх солі
NO20072893L (no) Fast, peroralt prevensjonsmiddel
CA2385755A1 (en) Prevention of colorectal cancer
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
WO2006138317A3 (en) Dosage regimen for prasugrel
JO3239B1 (ar) تركيبات جالينية من مركبات عضوية
EA200801890A1 (ru) Средство для лечения шума в ушах